Funding for this research was provided by:
National Heart, Lung, and Blood Institute (R01 HL136659)
Received: 14 September 2022
Accepted: 4 November 2022
First Online: 22 November 2022
: UK Biobank received ethical approval from the Research Ethics Committee (REC reference for UK Biobank is 11/NW/0382). The INTERVAL study was approved by the Cambridge (East) Research Ethics Committee. Informed consent was obtained from all participants of the UK Biobank, UK BiLEVE, and INTERVAL studies. Patients and control subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) approved the FinnGen study protocol Nr HUS/990/2017. The FinnGen study is approved by Finnish Institute for Health and Welfare (THL), approval. number THL/2031/6.02.00/2017, amendments THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019, Digital and population data service agency VRK43431/2017–3, VRK/6909/2018–3, VRK/4415/2019–3 the Social Insurance Institution (KELA) KELA 58/522/2017, KELA 131/522/2018, KELA. 70/522/2019, KELA 98/522/2019, and Statistics Finland TK-53–1041-17.
: Not applicable.
: The authors declare that they have no competing interests.